DrBioRight 2.0: an LLM-powered bioinformatics chatbot for large-scale cancer functional proteomics analysis
Top Cited Papers
Open Access
- 6 March 2025
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-6
Abstract
Functional proteomics provides critical insights into cancer mechanisms, facilitating the discovery of novel biomarkers and therapeutic targets. We have developed a comprehensive cancer functional proteomics resource using reverse phase protein arrays, incorporating data from nearly 8000 patient samples from The Cancer Genome Atlas and approximately 900 samples from the Cancer Cell Line Encyclopedia. Our dataset includes a curated panel of nearly 500 high-quality antibodies, covering all major cancer hallmark pathways. To enhance the accessibility and analytic power of this resource, we introduce DrBioRight 2.0 (https://drbioright.org), an intuitive bioinformatic platform powered by state-of-the-art large language models. DrBioRight enables researchers to explore protein-centric cancer omics data, perform advanced analyses, visualize results, and engage in interactive discussions using natural language. By streamlining complex proteogenomic analyses, this tool accelerates the translation of large-scale functional proteomics data into meaningful biomedical insights.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (U24264128)
This publication has 29 references indexed in Scilit:
- The Molecular Signatures Database Hallmark Gene Set CollectionCell Systems, 2015
- Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity DatasetCancer Discovery, 2015
- A pan-cancer proteomic perspective on The Cancer Genome AtlasNature Communications, 2014
- TCPA: a resource for cancer functional proteomics dataNature Methods, 2013
- An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small MoleculesCell, 2013
- Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cellsNucleic Acids Research, 2012
- Systematic identification of genomic markers of drug sensitivity in cancer cellsNature, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Non-parametric quantification of protein lysate arraysBioinformatics, 2007
- Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion frontOncogene, 2001